BYLieve:A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; Fulvestrant; Goserelin; Letrozole
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms BYLieve
- Sponsors Novartis; Novartis Pharmaceuticals
- 07 Jul 2019 Planned End Date changed from 30 Sep 2020 to 30 Nov 2021.
- 07 Jul 2019 Planned primary completion date changed from 10 Apr 2020 to 30 Nov 2020.
- 01 Mar 2019 Planned End Date changed from 27 Nov 2020 to 30 Sep 2020.